You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Prescription medicine BPR update newsletter, April 2012
The Prescription medicine BPR update (BPR update) reports on progress of the streamlined submission process. Each quarter, an update is provided on the PI/CMI project and the AusPAR project.
In this edition:
- New name for the BPR update
- Streamlined submission process
- Management of physical dossiers
- Case management function
- Fee arrangements
- PI/CMI project
- AusPAR project
The BPR newsletter was introduced to communicate updates and issues relating to the implementation of the streamlined submission process for prescription medicines. This involved a business process review (BPR) followed by the implementation of the streamlined submission process (SSP) in November 2010. This new process is now business as usual. Given that the SSP is just out of the transition period, there remains a need for the TGA to communicate information and issues to our industry stakeholders. Feedback from the Industry Working Group identified the BPR Update as a useful way to do this. Therefore, we will continue to publish a regular update newsletter, but commencing with the next edition, it will be called the TGA Prescription Medicines SSP Newsletter (SSP Newsletter).
The following is a summary of key statistics from applications lodged under the streamlined submission process to date. Due to the expansion and complexity of the summary statistics table, TGA will provide future progress to date of the streamlined submission process in a graph format.
- February 2012 batch
- 35 PPFs lodged
- 57% nominated 60-day response period to s. 31 request
- Included:- new entity - 2; new fixed combination - 1; generic - 11; minor variation - 14; major variation - 2
- March 2012 batch
- 26 PPFs lodged
- 88% nominated 60-day response period to s. 31 request
- Included:- new entity - 2 new fixed combination - 2; generic - 15; minor variation - 1; major variation -1; changes to PI - 5
- April 2012 batch
|Pre-submission planning forms|
|Not effective||1||0||1||0||0||1||2||1||1||1||2||1||TBA||3||1 (TBA - 3)||TBA||TBA||TBA|
* Deficiencies in the PPFs and submission dossiers are not applicable (N/A) for these batches due to the end of the transitional 48 hour grace period on 31 Oct 2011. Please refer to the November 2011 BPR Update regarding that announcement.
Section 31 letter
100% of the Section 31 letters due to be sent in the month of March were sent on time.
Results of second round evaluations
94% of the second round evaluations that were due to be sent out in March were sent on time.
The following is a summary of the number of calendar days taken to process specific types of applications from lodgement to decision of a submission. The data compares the quarterly average duration before and after the introduction of the streamlined submission process. During the reporting period one NCE was completed.
|Application type||Days elapsed from acceptance to decision|
|Pre streamlined submission process||Streamlined submission process|
|Period when decision finalised||Oct-Dec 2010||Jan-Mar 2011||Apr-June 2011||Jul-Sep 2011||Oct-Dec 2011||Oct-Dec 2010||Jan-Mar 2011||Apr-June 2011||Jul-Sep 2011||Oct-Dec 2011||Jan-Mar 2012|
|New Generic - type D|
|Average Calendar Days||425||412||399||409||395||-||-||-||-||196||231|
|Average Work days||227||212||216||213||213||-||-||-||-||123||137|
|New Chemical Entities|
|Average Calendar Days||379||467||443||457||395||-||-||-||-||-||326|
|Average Work days||190||237||228||237||225||-||-||-||-||-||204|
|Extension of Indication - type C|
|Average Calendar Days||404||348||423||398||333||-||-||-||-||279||201|
|Average Work days||236||209||258||215||210||-||-||-||-||100||117|
|Major Variation - type F|
|Average Calendar Days||274||393||345||394||355||-||-||-||-||-||246|
|Average Work days||168||207||199||211||204||-||-||-||-||-||140|
The following information draws on common issues identified with pre-submission planning forms (PPF) lodged to date under the streamlined submission process. This information applies to all applications lodged under the streamlined submission process.
|Deficiency||TGA requirement||TGA workflow impact|
|Section 1.7 - GMP license or clearance scheduled to expire||
It is a TGA requirement that for all manufacturers and finished product testing facilities involved in the active ingredient and/or product manufacture the sponsor must provide GMP licences or clearances with validity for at least 6 months after the scheduled full submission date.
If, the GMP licences or clearances are due to expire in this period of time then the Certification Tracking Number for the renewal application lodged with the Office of Manufacturing Quality (OMQ) must be provided in Module 1.7.3 of the PPF.
For more info:
The TGA uses manufacturing licences (for Australian manufacturing sites) and good manufacturing practice (GMP) clearances (for overseas sites) to establish whether the manufacturing/processing standards are acceptable.
Without valid manufacturing licences or GMP clearances, the TGA cannot evaluate the submission.
|Section 1.6 - Drug Master File (DMF)||
If the pre-submission form indicates that the submission will be making a reference to a Drug Master File then it is a TGA requirement that the Drug Master File number is provided in Section 1.6 of the PPF and the DMF is supplied both electronically and in hard copy prior to the submission dossier.
For more info:
The TGA requires that relevant DMF copies and details are provided with the PPF to enable access to information regarding the active substance at the time of submission. Without this information the TGA is unable to access essential information and evaluate the submission.
|Part 2 - Details of submission||
The TGA is aware that there remain different understandings across industry regarding the TGA requirements to determine the scope and scale of an evaluation.
The TGA would like to confirm that to ensure a PPF is accepted the requirements, instructions and explanations in the current (March 2011) PPF form and Information for sponsors completing a pre-submission planning form published on the TGA website is to be adhered to.
Any alterations to the requirements will be only through the modification of the PPF form and associated publications.
For further questions contact the case management team: firstname.lastname@example.org
TGA requires the necessary information to arrange appropriate resourcing for the processing and evaluation of an application, including where relevant, the contracting of external evaluators.
The information provided in the PPF allows the TGA to commit to timeframes for the evaluation of the application.
The TGA is currently conducting a review of the performance of the streamlined submission process to date with a view to indentifying refinements and pressure points that are barriers to meeting milestone dates. The initial stages of the project will focus on milestones 5 to 8. The TGA will engage with the Industry Working Group on proposed refinements and solutions to identified pressure points, including communicating the outcomes and any process changes to address the identified process improvements.
The streamlined submission process is based on a series of milestones, some of which involve the TGA providing certain information to sponsors, such as the planning letter at milestone 1 or the notification letter at milestone 2.
Since May 2011, the TGA has generally not been able to meet the milestone dates associated with milestones 1 – 3. A number of reasons can be provided, such as
- resource challenges posed by the double-processing of applications under the previous process and the streamlined submission process,
- insufficient evaluation resources available to assess submissions; and
- additional workloads associated with the 48 hour ‘grace period’ that applied during the 12 month transition period.
The TGA has been taking action to address this issue, including procuring additional external evaluation resources to assist with clearing the backlog and assessing procedural options to improve our ability to meet these milestones. A key strategy has been to establish the case manager function, which was implemented in December 2011. The TGA announced this development in the December 2011 BPR Update.
Early indications show that these actions are having an impact. For instance, 84% of the planning letters for the combined December 2011/January 2012 batch were provided to sponsors within 3 days of the milestone 1 date. Given that this relates to 68 applications received in this batch and covers the TGA shutdown period and summer vacations for staff, it indicates that in the next few months we should see more milestone dates being met. The TGA is collating information that will allow more accurate reporting against this performance indicator.
Over the Christmas - New Year period, the TGA was required to revise administrative arrangements for the handling of a small number of hardcopy submissions provided in non-standard folder sizes.
The TGA would like to reiterate the hardcopy format constraints to Sponsors (CTD Module 1 Part A Mandatory requirements for hardcopy submission dossiers). To ensure efficient streamlined processing of hardcopy submissions upon receipt at the TGA, external dimensions of folders should not exceed 270mm wide x 320mm high x 80mm thick.
Submissions comprised of folders larger than the specified dimensions may be subject to delays due to the additional effort required by records management staff in processing the submission.
The TGA is currently considering options for preventative action to ensure all submission dossiers can be processed efficiently.
The case management function announced in the December 2011 BPR update is being rolled out with the December 2011/January 2012 combined batch of submissions.
The functions of the case managers are to support TGA evaluators and delegates and to coordinate and track applications through the pre-market authorisation process. They will establish and maintain a central coordination role in monitoring applications across the different prescription medicines evaluation areas from the pre-submission phase through to the final decision phase. The case management team will also seek regular feedback to measure effectiveness of the streamlined submission process and propose business processes improvements as needed.
The case managers will be the main point of contact for sponsors, as well as internal delegates, administration and evaluation areas and the ACPM Secretariat. They will be well placed to respond to sponsor needs and concerns, both application-related and more broadly via the Industry Working Group (IWG).
All contact with case managers should be conducted through the streamlined submission mailbox:
The TGA requests that sponsors address the subject line in the following manner:
- PM-XXXX-XXXXX-X-X Sponsor name active ingredient.
5.1 Online invoice generation for application fee payments through the streamlined submission process
Applicants are advised that the electronic Business Services (eBS) portal has been enhanced to automatically generate an invoice for an application fee after lodgement of a pre-submission planning form (PPF).
As detailed in the July 2011 BPR Update, new fee arrangements for submissions lodged under the streamlined submission process commenced in July 2011. The new fee arrangements resulted from amendments to the Therapeutic Good Regulations 1990. Due to the changes in the legislation, there was a need to develop and implement enhancements to the TGA’s online lodgement system (eBS). These changes are complete and applicants can now generate electronic invoices for application fees upon lodgement of their pre-submission planning form (PPF).
The TGA reminds applicants that an application fee is due and payable upon lodgement of the PPF. Please refer to the Summary of fees and charges to determine the relevant application fee for the application submitted. Paragraph 23(2)(a) of the Therapeutic Goods Act 1989 (the Act) states than an application is not effective unless the application fee has been paid.
Applicants should continue to submit their payment directly to the TGA finance area using one of the prescribed payment methods and quoting the invoice number (e.g. ONLxxxxxx).
When the TGA accepts an application for evaluation, the applicant will be sent a Notification Letter as confirmation. The Notification Letter will specify the type of evaluation and the evaluation fee. Under section 24A of the Act, the evaluation fee is due and payable on the day the applicant is notified of the amount of the evaluation fee.
Under paragraph 24(2)(a) of the Act, an application lapses two months after the day on which the evaluation fee became due and payable (i.e., when the applicant was notified of the fee). The Act does not contain any provisions to grant extensions to applicants that fail to pay within this time. Payments can be made directly to the TGA finance area using one of the prescribed payment methods quoting the submission number (e.g. PM-2012-xxxxx-x) and Client I.D. or, upon being invoiced by the TGA.
It is the responsibility of the applicant to correctly identify the application to which the payment relates including payments made via EFTPOS. Identification of the application can occur through reference of the submission number (e.g. PM-xxxx-xxxx-x) or the invoice number (INV xxxxx, ONLxxxxxx).
The TGA aims to improve access for consumers and health professionals to information about prescription medicines by providing a single trusted internet source for PI and CMI documents.
To achieve this, the TGA collects the following:
- PI documents for all prescription medicines registered on the Australian Register of Therapeutic Goods (ARTG), whether they are marketed or not
- CMI documents for all registered prescription medicines on the ARTG that are being marketed in Australia.
In addition to supplying PI and CMI documents for existing registrations, sponsors must lodge PIs and CMIs with the TGA following approval of applications for new and varied products. Lodgement of PI and CMI documents must be completed electronically via the secure eBS facility.
Published PI and CMI documents are available on the TGA eBS website at www.ebs.tga.gov.au under 'Public TGA information'.
The following table shows progress in publishing PI and CMI documents as at 20 February 2012.
|Document||As percentage of prescription medicine entries on the ARTG|
|January 2011||March 2011||June 2011||November 2011||February 2012|
|Total ARTG entries||10,043||10,125||10,838||11,025|
A product information (PI) or consumer medicines information (CMI) document is only to be lodged once all changes made are considered acceptable by the TGA and the sponsor has received formal approval or acknowledgement in the form of a signed letter from the TGA delegate. This applies to category 1, category 2, category 3, Safety Related Notification (SRN), Self Assessable Notification (SAN) and Minor Editorial Change (MEC) applications. Documents are not to be lodged on the TGA eBS PI/CMI facility until such time that approval has been granted.
The following table provides an update on AusPAR progress to 28 February 2012.
|as at 31 Dec 2010||as at 30 April 2011||as at 30 Jun 2011||as at 1 Dec 2011||as at 28 Feb 2012|
|Released on TGA website||74||102||116||146||164|
|With sponsors for comment||4||7||6||6||8|
Waiting for either:
|Initial draft complete and waiting for the delegate's decision||16||6||-||4||5|
|Undergoing final internal TGA quality assurance review||12||7||10||4||1|
For further enquires please email: email@example.com
© Commonwealth of Australia 2011
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to firstname.lastname@example.org.